Biohaven Ltd. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Biohaven Ltd. (BHVN) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price of $18.72 per share as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice · last filed 2026-08-10
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $18.72.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $18.84.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $21.06.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $21.11.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price as first filed |
|---|---|---|
| 2026-06-30 | $18.72 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $18.84 10-Q · filed 2026-05-04 | |
| 2025-12-31 | $21.06 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $21.11 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $21.18 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $21.20 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $17.46 10-K · filed 2026-03-02 | |
| 2024-09-30 | $17.36 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $17.15 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $16.95 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $11.48 10-K · filed 2025-03-03 | |
| 2022-12-31 | $7.00 10-K · filed 2023-03-23 | |
| 2022-10-03 | $7.00 10-K · filed 2024-02-29 | $0.00 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |